TW202337495A - 用satralizumab治療自體免疫腦炎 - Google Patents

用satralizumab治療自體免疫腦炎 Download PDF

Info

Publication number
TW202337495A
TW202337495A TW112102365A TW112102365A TW202337495A TW 202337495 A TW202337495 A TW 202337495A TW 112102365 A TW112102365 A TW 112102365A TW 112102365 A TW112102365 A TW 112102365A TW 202337495 A TW202337495 A TW 202337495A
Authority
TW
Taiwan
Prior art keywords
encephalitis
administered
nmdar
individual
lgi1
Prior art date
Application number
TW112102365A
Other languages
English (en)
Chinese (zh)
Inventor
小澤孝俊
井田広顕
伊藤創
吉田俊介
吉莉安 史密斯
克萊姆斯 希恩 藍儂
蓋勒 克蘭傑史密特
比丁根 漢斯 克里斯蒂安 馮
包曼 漢娜 席柏
詹姆士 奧弗雷爾
莎蜜菈 拉詹
Original Assignee
日商中外製藥股份有限公司
瑞士商赫孚孟拉羅股份公司
美商建南德克公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商中外製藥股份有限公司, 瑞士商赫孚孟拉羅股份公司, 美商建南德克公司 filed Critical 日商中外製藥股份有限公司
Publication of TW202337495A publication Critical patent/TW202337495A/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW112102365A 2022-01-19 2023-01-18 用satralizumab治療自體免疫腦炎 TW202337495A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263300893P 2022-01-19 2022-01-19
US63/300,893 2022-01-19

Publications (1)

Publication Number Publication Date
TW202337495A true TW202337495A (zh) 2023-10-01

Family

ID=87348849

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112102365A TW202337495A (zh) 2022-01-19 2023-01-18 用satralizumab治療自體免疫腦炎

Country Status (11)

Country Link
US (1) US20250127891A1 (https=)
EP (1) EP4466018A4 (https=)
JP (1) JP2025502891A (https=)
KR (1) KR20240145472A (https=)
CN (1) CN118900699A (https=)
AU (1) AU2023209259A1 (https=)
CA (1) CA3243067A1 (https=)
IL (1) IL314213A (https=)
MX (1) MX2024008835A (https=)
TW (1) TW202337495A (https=)
WO (1) WO2023140269A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2892925T3 (es) 2006-03-31 2022-02-07 Chugai Pharmaceutical Co Ltd Métodos para controlar la farmacocinética en sangre de anticuerpos
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
WO2019151418A1 (ja) 2018-01-31 2019-08-08 元一 加藤 Il-6阻害剤を含有する喘息の治療剤
IL287220B2 (en) 2019-04-17 2026-03-01 Univ Hiroshima A therapeutic agent for urological cancer characterized by administering an IL-6 inhibitor in combination with a CCR2 inhibitor
AU2021278562A1 (en) 2020-05-29 2022-12-01 Chugai Seiyaku Kabushiki Kaisha Antibody-containing formulation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2206775B1 (en) 2007-09-26 2016-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-il-6 receptor antibody
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US20120039840A1 (en) 2008-12-02 2012-02-16 Hunter Christopher A Use of IL-27-P28 to antagonize IL-6 mediated signaling
JP6130983B2 (ja) 2015-02-27 2017-05-17 中外製薬株式会社 Il−6関連疾患治療用組成物
JPWO2020202839A1 (https=) * 2019-03-29 2020-10-08

Also Published As

Publication number Publication date
EP4466018A4 (en) 2026-03-25
MX2024008835A (es) 2024-07-25
CA3243067A1 (en) 2023-07-27
CN118900699A (zh) 2024-11-05
IL314213A (en) 2024-09-01
AU2023209259A1 (en) 2024-07-18
JP2025502891A (ja) 2025-01-28
WO2023140269A1 (en) 2023-07-27
EP4466018A1 (en) 2024-11-27
US20250127891A1 (en) 2025-04-24
KR20240145472A (ko) 2024-10-07

Similar Documents

Publication Publication Date Title
WO2023140269A1 (en) Treatment of autoimmune encephalitis with satralizumab
WO2023095852A1 (en) Treatment of a demyelinating disease of the central nervous system (cns) with satralizumab
CA2490186C (en) Method for the treatment of multiple sclerosis
US20220396630A1 (en) Type i interferon inhibition in systemic lupus erythematosus
US20230183362A1 (en) Methods for treating prurigo nodularis by administering an il-4r antagonist
US20220356261A1 (en) Treatment for sjögren's syndrome
TW202233676A (zh) 使用抗cd19抗體治療自體免疫性疾病
CN116322765A (zh) 用于用奥瑞珠单抗治疗多发性硬化症的方法
HK40111127A (zh) 使用萨特利珠单抗治疗自身免疫性脑炎
US20240270842A1 (en) Use of an anti-cd19 antibody to treat myasthenia gravis
JP2022180487A (ja) Htlv-1関連脊髄症(ham)治療又は予防剤、及びhamの治療方法
KR102628314B1 (ko) 화농성 한선염 치료를 위한 범-elr+ cxc 케모카인 항체
HK40107811A (zh) 使用萨特利珠单抗治疗中枢神经系统(cns)的脱髓鞘疾病
US20250066467A1 (en) Methods for the treatment of myasthenia gravis
EA052907B1 (ru) Применение антитела к cd19 для лечения миастении гравис
JP2018526404A (ja) 再発型の多発性硬化症を治療するための方法